TRBC1/2-Targeted CAR-T Cell Therapy (Second Affiliated Hospital School Of Zhejiang University School Of Medicine)

N/A

Report date: 2026/04/03 20:03:44

Base Information

Drug NameTRBC1/2-Targeted CAR-T Cell Therapy (Second Affiliated Hospital School Of Zhejiang University School Of Medicine)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-TRBC1T lymphocyte replacements

TargetsTRBC1

Therapy Area/IndicationsLymphoma, T-Cell, Peripheral

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesSecond Affiliated Hospital School Of Zhejiang University School Of Medicine

China Registration ClassN/A

Develop Information

Active CompaniesSecond Affiliated Hospital School Of Zhejiang University School Of Medicine

Inactive CompaniesN/A

Active IndicationsLymphoma, T-Cell, Peripheral

Inactive IndicationsN/A

Other Information

ATC CodeN/A